{"a":[{"_":"FDA approves first radioligand equivalent, Curium’s copycat of Novartis’ Lutathera","$":{"href":"/pharma/fda-approves-first-radioligand-equivalent-curiums-copycat-novartis-lutathera","hreflang":"en"}}]}
RegulatoryapprovedBexlutryLutatheraPositive
AI Analysis
Summary
The FDA approved Curium's Bexlutry (lutetium Lu 177 dotatate injection), the industry's first radioligand equivalent to Novartis' Lutathera, following a court decision clearing Curium of all patent infringement claims brought by Novartis.
Outcome Details
FDA approved first radioligand equivalent after patent litigation cleared
Importance:8/10
Sentiment:
0.70
FDA ApprovalRadioligandBiosimilar/Generic EquivalentPatent LitigationOncology
Related Companies
Read the original article
Published by FiercePharma on September 15, 2026 8:41 AM